argenx NV ADR

Stock Chart, Company Information, and Scan Results

$731.77(as of Sep 18, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

argenx NV ADR Company Information, Fundamentals, and Technical Indicators

Stock Price$731.77
Ticker SymbolARGX
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees1,599
CountyUSA
Market Cap$45,396.7M
EBIDTA469.0M
10-Day Moving Average754.38
P/E Ratio35.02
20-Day Moving Average726.96
Forward P/E Ratio29.59
50-Day Moving Average662.20
Earnings per Share19.68
200-Day Moving Average619.39
Profit Margin25.88%
RSI59.09
Shares Outstanding61.2M
ATR17.10
52-Week High779.03
Volume380,835
52-Week Low510.06
Most Recent Support Level745.91
Book Value6,095.8M
Most Recent Resistance Level759.79
P/B Ratio7.88
Upper Keltner765.43
P/S Ratio13.13
Lower Keltner688.49
Debt-to-Equity Ratio765.43
Next Earnings Date10/30/2025
Cash Surplus1,044.1M
Next Ex-Dividend DateUnknown

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

argenx NV ADR In Our Stock Scanner

As of Sep 19, 2025
example chart graphic
Scan Name: Doji CandlesScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Long Legged DojiScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Uptrending StocksScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Increasing Book ValueScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.